Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Transgene Announces Promising Results in an Update from the Phase 2b Part of TIME Trial with TG4010 in Advanced Non-Small Cell Lung Cancer

"Transgene SA (TNG.PA) (TNG.PA) today announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial1 with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).


"Following an analysis conducted with a more mature dataset, the primary endpoint of progression-free survival (PFS) to validate the TrPAL predictive biomarker was met2 in the normal TrPAL3 group. The high TrPAL group had not yet met the required number of events to conduct the primary analysis."


Editor's note: This clinical trial is testing whether an immunotherapy drug called TG4010 MUC-1 might be effective for some patients with non-small cell lung cancer (NSCLC). For more information, see this trial in our Clinical Trial Finder.

Cancer Commons's insight:

Yahoo!  |  May 27, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Clinical Trial to Examine Effectiveness of Lung Cancer Vaccine TG4010 in Select Patients

A new clinical trial will examine the effectiveness of the lung cancer drug TG4010. TG4010 acts like a vaccine: it sensitizes the immune system to MUC1, a protein expressed in high levels on many lung tumor cells, and thus primes the immune system to attack these cancer cells. A previous trial suggested that TG4010 is most likely to be effective in patients with low levels of a certain kind of immune cell called triple-positive activated lymphocytes or TrPAL. In the new trial, patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of MUC1 and who have low levels of TrPAL will receive either TG4010 or a placebo along with their standard treatment.

Cancer Commons's insight:

Bloomberg  |  Jan 8, 2014

more...
No comment yet.